A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
212actual
Sites
2
Countries
Cyprus, Greece
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-07 | actual | When the study began enrolling |
| Primary completion | 2025-10-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-31 | actual | The whole study's end, after follow-up |
| First posted | 2021-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Primary outcomes
what the primary-completion date above is the date OFProportion of participants surviving at the landmark timepoint of 12 months after the initiation of nivolumab treatment, in the overall study population
measured Up to 12 months
Proportion of participants surviving at the landmark timepoint of 24 months after the initiation of nivolumab treatment, in the overall study population
measured Up to 24 months
Proportion of participants surviving at the landmark timepoint of 36 months after the initiation of nivolumab treatment, in the overall study population
measured Up to 36 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed